In short
Nurix Therapeutics, Inc. (NRIX) has revenue up 54.0% to $84.0M and net income down 36.6% to -$264.5M year on year. Fisclear flags 2 high-severity risks, led by: Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability. How we calculate this
Valuation
HealthcareLive · Yahoo FinancePrice
$12.85
$1.4B
1.4x
52-Week Range
Decision Context
Below-average scores in Efficiency, Cashflow. The data points to fundamental challenges that outweigh near-term macro considerations.
Based on filing period ending Aug 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.75%
Accommodative
10-Year Treasury
4.99%
2026-09-01
Unemployment
4.2%
Near full employment
CPI Index
334.1
2026-08-01
M2 Money Supply
$23.3T
2026-08-01
The Federal Funds rate stands at 3.75% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.99%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 103.1; M2 money supply is $23.3T; CPI index stands at 334.1.
SWOT Analysis — NRIX
Inflationary BoomStrengths
Revenue: $84.0M (+54.0% YoY) — Revenue grew 54% — the company sold more goods or services than the prior year.
Weaknesses
Operating Cash Flow: -$249.5M (-44.5% YoY) — Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income: -$264.5M (-36.6% YoY) — The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted): $-3.05 (-5.9% YoY) — Negative EPS — the company recorded a loss on a per-share basis.
R&D spending is 377% of revenue — heavy investment in future growth, but also a drag on current profitability.
Beta of 1.82x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.
Opportunities
Total Assets: $688.1M (+2.8% YoY) — Total assets grew 3% — the company's resource base expanded.
Threats
Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.
Negative operating cash flow of $249.5M — the core business consumed more cash than it generated.
Year-over-Year Changes
Revenue
$84.0M
was $54.5M
Revenue grew 54% — the company sold more goods or services than the prior year.
Operating Cash Flow
-$249.5M
was -$172.6M
Negative operating cash flow — the business consumed more cash than it produced from operations.
Net Income
-$264.5M
was -$193.6M
The company posted a net loss — total expenses exceeded total revenue.
EPS (Diluted)
$-3.05
was $-2.88
Negative EPS — the company recorded a loss on a per-share basis.
Total Assets
$688.1M
was $669.3M
Total assets grew 3% — the company's resource base expanded.
Risk Flags
2 high · 0 medium · 2 low- ⚠ High
Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.
- ⚠ High
Negative operating cash flow of $249.5M — the core business consumed more cash than it generated.
- ○ Low
R&D spending is 377% of revenue — heavy investment in future growth, but also a drag on current profitability.
- ○ Low
Beta of 1.82x — this stock moves significantly more than the broader market, amplifying both gains and drawdowns.
Technical Signals
Daily closes · 1-year dataNurix Therapeutics, Inc.: common questions
Is Nurix Therapeutics, Inc. profitable?
No. Nurix Therapeutics, Inc. reported a net loss of $264M in its latest fiscal year (fiscal 2025).
Is Nurix Therapeutics, Inc.'s revenue growing?
Yes. Revenue grew 54.0% year on year, to $84.0M.
What is Nurix Therapeutics, Inc.'s P/E ratio?
Nurix Therapeutics, Inc. trades at 5.3× its trailing twelve-month earnings. In other words, the share price is about 5 times the profit per share the company earned over the past year.
Does Nurix Therapeutics, Inc. pay a dividend?
No dividend is currently expected from Nurix Therapeutics, Inc., according to the latest market data.
What are the main risks for Nurix Therapeutics, Inc.?
Fisclear's checks flag 2 medium- or high-severity risks. The most serious: Net loss of $264.5M — the company spent more than it earned. Investors should monitor the path to profitability.
Answers are generated from the figures in this report (updated 13 Oct 2026). Information, not investment advice.
Latest News
via FinnhubFiling History — NRIX
Get the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade NRIX
Links open broker research pages. Not an endorsement or recommendation.
Research Nurix Therapeutics, Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.